Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.75, read 2026-11-01
Ethical does not pass the values gate
Price118.19 USD
Fair value122.59
Ethical score10.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-29Read Markup117.06+1.0% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-02Read Markdown118.42-0.2% to today ✓Markup gives way to Markdown after a 16% slide in 6 weeks
2026-08-24Read Markup141.35-16.4% to today Distribution gives way to Markup after a 23% rise in 8 weeks
2026-07-02Read Distribution115.35+2.5% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Blackstone Inc. holds its Markup at $118.19. The statistical read favours the sellers, held for 338 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 338 days
Price at the screen
$118.19
Valuation
26.86 trailing · 16.34 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.59
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Blackstone does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BX's ethical verdict changes
Today BX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades at roughly a 2% discount to our $122.59 fair value, strong competitive moat.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 3.6% discount to the base estimate.
Third-party analyst targets: 22 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Imagine a financial titan that can move markets, a firm that's as much a part of Wall Street's fabric as the Charging Bull statue. That's Blackstone Inc., an alternative asset manager with a strong moat in private equity and real estate. It stands out with a robust revenue growth of 29%, a profit margin of 23%, and an ROE of 31%, numbers that would typically make investors sit up and take notice.
However, despite these attractive financials, Blackstone fails our ethical screen, a critical measure in today's investing landscape. It's not the numbers that are the issue here, but the firm's business activities that lead to an ethical failing. This is a red flag that goes beyond the allure of high returns and growth prospects.
The market consensus is a buy, with a median target of $140, which is perilously close to the current price, offering little margin of safety. Coupled with the ethical failings, this analysis suggests caution. The allure of strong financial metrics is undeniable, but the ethical dimension is a non-negotiable part of our investment thesis. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup · changed$117.06+7.2%Entry 22
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144.
2026-10-22Markdown$109.20+0.0%Entry 21
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$109.20+0.0%Entry 20
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$109.20+0.0%Entry 19
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$109.20+0.0%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$109.20+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$109.20+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$109.20-4.5%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$114.29+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$114.29-3.5%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (20 analysts) rates it buy, with a mean price target of $144.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
